US equities
|
SPCX
$166.75
▲+4.90%
NVDA
$236.67
▲+1.16%
MU
$1,064.12
▼-1.00%
TSLA
$377.74
▲+1.93%
MSFT
$525.54
▲+1.55%
SNDK
$1,711.50
▼-0.49%
INTC
$117.13
▼-1.84%
META
$745.80
▲+2.43%
SPCX
$166.75
▲+4.90%
NVDA
$236.67
▲+1.16%
MU
$1,064.12
▼-1.00%
TSLA
$377.74
▲+1.93%
MSFT
$525.54
▲+1.55%
SNDK
$1,711.50
▼-0.49%
INTC
$117.13
▼-1.84%
META
$745.80
▲+2.43%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Relay Therapeutics, Inc. - Common Stock
(NQ:
RLAY
)
18.73
-0.23 (-1.21%)
Delayed Quote
Updated: 11:44 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Relay Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
↗
September 02, 2026
Catinazzo's pre-arranged sale reduced his direct stake by 11%, but the insider still holds a significant amount of shares.
Via
The Motley Fool
Topics
Regulatory Compliance
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
September 01, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics (NASDAQ:RLAY) Reports Q2 2026 Revenue Miss as Loss Widens Slightly
↗
August 06, 2026
Via
Chartmill
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
August 06, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
July 30, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics (NASDAQ:RLAY) Beats Q1 Estimates but Slips on Wider Loss and Lack of Guidance
↗
May 05, 2026
Via
Chartmill
Relay Therapeutics Inc (NASDAQ:RLAY) Beats Q4 Revenue Estimates, Outlines Pivotal 2026 for Zovegalisib
↗
February 26, 2026
Via
Chartmill
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
↗
June 29, 2026
This precision oncology innovator, up nearly 500% in a year, just reported significant insider selling amid ongoing drug development efforts.
Via
The Motley Fool
Topics
Regulatory Compliance
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
May 27, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Is Relay Therapeutics a Buy After Promising Trial Results?
↗
May 22, 2026
Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy.
Via
The Motley Fool
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
May 20, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Why Relay Therapeutics Stock Popped on Wednesday
↗
May 20, 2026
In a way, this was a delayed reaction to excellent news from the lab.
Via
The Motley Fool
Relay Therapeutics Announces Proposed Public Offering of Common Stock
May 19, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
May 19, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
↗
May 18, 2026
Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified research pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Energy Vault Stock Has Surged 500%. One Major Holder Just Sold 3 Million Shares
↗
May 18, 2026
Energy Vault Holdings develops modular, grid-scale energy storage systems for utilities and large-scale power users.
Via
The Motley Fool
Topics
Regulatory Compliance
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
May 05, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
April 29, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
April 27, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
April 02, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
↗
March 19, 2026
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.
Via
The Motley Fool
Nextech Trims Kymera at a Recent High — think Foolishly before acting.
↗
March 19, 2026
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
March 16, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million
↗
February 27, 2026
Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.
Via
The Motley Fool
Topics
Regulatory Compliance
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million
↗
February 27, 2026
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
Via
The Motley Fool
Topics
Regulatory Compliance
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
February 26, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
February 23, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
↗
February 23, 2026
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.
Via
The Motley Fool
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
↗
February 23, 2026
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Via
The Motley Fool
Topics
Regulatory Compliance
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million
↗
February 23, 2026
Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
